Allogene Therapeutics (ALLO) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 19.5% versus a loss of 4.8%. Over five years, ALLO leads with a -91.3% price change compared with -93.2% for CBIO. Crescent Biopharma is the larger company by market cap ($524.5 million vs $483.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | CBIO |
|---|---|---|
| Share price | $1.40 | $14.12 |
| Market cap | $483.69M | $524.51M |
| 1-day change | -2.10% | +4.67% |
| YTD return | +2.19% | +13.74% |
| 1-year return | -4.76% | +19.49% |
| 5-year return | -91.32% | -93.19% |
| EPS (TTM) | $-0.66 | $-7.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $27.41 |
| 52-week low | $1.04 | $8.72 |
| Distance from 52-week high | -68.61% | -48.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +542.86% | +123.09% |
| Average volume | 5.65M | 397.58K |
| Shares outstanding | 345.49M | 37.14M |
| Employees | 150 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed ALLO by 24.2 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ALLO vs CBIO FAQ
Which is bigger, Allogene Therapeutics or Crescent Biopharma?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $524.51M compared with $483.69M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or CBIO?
CBIO returned +19.49% over the past 12 months, compared with -4.76% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Crescent Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Allogene Therapeutics and Biotechnology: Pharmaceutical Preparations for Crescent Biopharma.